Your browser doesn't support javascript.
loading
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Gold, Ralf; Arnold, Douglas L; Bar-Or, Amit; Fox, Robert J; Kappos, Ludwig; Mokliatchouk, Oksana; Jiang, Xiaotong; Lyons, Jennifer; Kapadia, Shivani; Miller, Catherine.
  • Gold R; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Arnold DL; Montreal Neurological Institute-Hospital, McGill University and NeuroRx Research, Montreal, QC, Canada.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Fox RJ; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland.
  • Mokliatchouk O; Biogen, Cambridge, MA, USA.
  • Jiang X; Biogen, Cambridge, MA, USA.
  • Lyons J; Biogen, Cambridge, MA, USA.
  • Kapadia S; Biogen, Cambridge, MA, USA.
  • Miller C; Biogen, Cambridge, MA, USA.
Mult Scler ; 28(5): 801-816, 2022 04.
Article en En | MEDLINE | ID: mdl-34465252
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article